All In Biotech

Drug Trial Radar · NCT02233647

Phendimetrazine and Cocaine

Safety and Tolerability of Cocaine During Phendimetrazine Maintenance

Last checked: Nov 20, 2026Latest source record: Sep 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

11

Actual

Start

Sep 2014

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
William StoopsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Sep 8, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Crossover
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will determine the safety and tolerability of phendimetrazine (Bontril®) as a pharmacotherapy for cocaine use disorder. A rigorous, inpatient human laboratory study will be conducted in which the subjective and physiological effects of cocaine are evaluated during maintenance on placebo and phendimetrazine.

Conditions

  • Cocaine Use Disorder

Interventions

  • CocaineDrug

    The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.

  • PlaceboDrug

    The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak Systolic PressureTime frame: This measure was completed at 15 minute intervals after sampling each cocaine dose under both phendimetrazine and placebo maintenance conditions.
  2. Peak Diastolic PressureTime frame: This measure was completed at 15 minute intervals after sampling each cocaine dose under both phendimetrazine and placebo maintenance conditions.
  3. Peak Heart RateTime frame: This measure was completed at 15 minute intervals after sampling each cocaine dose under both phendimetrazine and placebo maintenance conditions.
  4. Peak TemperatureTime frame: This measure was completed at 15 minute intervals after sampling each cocaine dose under both phendimetrazine and placebo maintenance conditions.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Kentucky Laboratory of Human Behavioral Pharmacology

    Lexington, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.